Table 1.
Demographics of Study Subjects With and Without GH Treatment
| GH Treatment (n = 338) |
No GH Treatment (n = 11 760) |
||||||
|---|---|---|---|---|---|---|---|
| GH Treatment (n = 338) | Meningioma (n = 10) | Glioma (n = 6) | No GH Treatment (n = 11 760) | Meningioma (n = 138) | Glioma (n = 49) | Other CNS SN (n = 16) | |
| Sexa | |||||||
| Male | 220 (65.1%) | 6 | 3 | 6147 (52.3%) | 53 | 28 | 6 |
| Female | 118 (34.9%) | 4 | 3 | 5613 (47.7%) | 85 | 21 | 10 |
| Race/ethnicity | |||||||
| White, non-Hispanic | 294 (87.0%) | 10 | 6 | 9951 (84.6%) | 118 | 39 | 15 |
| Black, non-Hispanic | 9 (2.7%) | 453 (3.9%) | 3 | 3 | |||
| Hispanic | 13 (3.8%) | 532 (4.5%) | 5 | 2 | |||
| Other, not specified | 22 (6.5%) | 824 (7.0%) | 12 | 5 | 1 | ||
| Primary cancer diagnosisa | |||||||
| Leukemia | 101 (29.9%) | 1 | 3 | 3980 (33.8%) | 80 | 23 | 9 |
| CNS tumor | 165 (48.8%) | 7 | 2 | 1353 (11.5%) | 47 | 15 | 2 |
| Hodgkin lymphoma | 1 (0.3%) | 1640 (13.9%) | 4 | 4 | 2 | ||
| Non-Hodgkin lymphoma | 10 (3.0%) | 1 | 881 (7.5%) | 2 | 3 | ||
| Wilms' tumor | 1 (0.3%) | 1061 (9.0%) | 1 | ||||
| Neuroblastoma | 16 (4.7%) | 1 | 800 (6.8%) | 1 | 1 | ||
| Soft tissue sarcomas | 42 (12.4%) | 1 | 1013 (8.6%) | 3 | 1 | 1 | |
| Bone malignancies | 2 (0.6%) | 1032 (8.8%) | 2 | 2 | |||
| Age at primary cancer diagnosis, ya | |||||||
| 0–4 | 221 (65.4%) | 5 | 4 | 4579 (38.9%) | 67 | 25 | 12 |
| 5–9 | 97 (28.7%) | 4 | 1 | 2556 (21.7%) | 38 | 7 | 2 |
| 10–14 | 19 (5.6%) | 1 | 1 | 2444 (20.8%) | 20 | 12 | 2 |
| 15+ | 1 (0.3%) | 2181 (18.5%) | 13 | 5 | |||
| Age at diagnosis of CNS SN, y | |||||||
| 0–9.9 | 2 | 8 | 1 | ||||
| 10–19.9 | 3 | 4 | 12 | 16 | 6 | ||
| 20–29.9 | 5 | 2 | 69 | 12 | 5 | ||
| 30–39.9 | 45 | 10 | 3 | ||||
| 40+ | 12 | 3 | 1 | ||||
| Treatment for original cancera | |||||||
| Surgery only | 1 (0.3%) | 900 (7.7%) | 1 | 3 | |||
| Radiation only | 2 (0.6%) | 36 (0.3%) | 1 | 1 | |||
| Chemotherapy only | 6 (1.8%) | 1 | 879 (7.5%) | 2 | 1 | ||
| Surgery/radiation | 71 (21.0%) | 2 | 2 | 1358 (11.5%) | 37 | 11 | 2 |
| Surgery/chemotherapy | 8 (2.4%) | 2222 (18.9%) | 1 | 1 | 2 | ||
| Radiation/chemotherapy | 43 (12.7%) | 1 | 1563 (13.3%) | 56 | 9 | 5 | |
| Surgery/radiation/chemotherapy | 205 (60.7%) | 8 | 2 | 4662 (39.6%) | 40 | 23 | 7 |
| Unknown | 2 (0.6%) | 140 (1.2%) | |||||
| Recurrence prior to first SNa | |||||||
| Yes | 8 (2.4%) | 1 | 1 | 178 (1.5%) | 19 | 7 | 6 |
| Radiation dose to braina | |||||||
| No CRT radiation | 22 (6.5%) | 1 | 7392 (62.9%) | 8 | 10 | 4 | |
| <10 Gy | 13 (3.8%) | 370 (3.1%) | 2 | 1 | 2 | ||
| 10–19.9 Gy | 32 (9.5%) | 1168 (9.9%) | 17 | 9 | 1 | ||
| 20–29.9 Gy | 50 (14.8%) | 1 | 1 | 1303 (11.1%) | 55 | 13 | 5 |
| 30–45 Gy | 36 (10.7%) | 1 | 295 (2.5%) | 12 | 1 | 3 | |
| >45 Gy | 172 (50.9%) | 7 | 4 | 838 (7.1%) | 43 | 13 | 1 |
| Unknown | 13 (3.8%) | 1 | 394 (3.4%) | 1 | 2 | ||
| Estrogen/progesterone treatment | |||||||
| Yes | 80 (23.7%) | 1 | 2 | 3393 (28.9%) | 47 | 10 | 2 |
| Intrathecal methotrexate | |||||||
| Yes | 128 (37.9%) | 1 | 3 | 4251 (36.1%) | 75 | 23 | 9 |
| Alkylating agenta | |||||||
| Yes | 218 (64.5%) | 7 | 3 | 6060 (51.5%) | 44 | 22 | 10 |
a
P < .05, comparing those with GH treatment with those without GH treatment.